Equities Analysts Issue Forecasts for Supernus Pharmaceuticals Inc’s FY2022 Earnings (SUPN)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – Research analysts at B. Riley issued their FY2022 EPS estimates for shares of Supernus Pharmaceuticals in a note issued to investors on Thursday. B. Riley analyst D. Buck anticipates that the specialty pharmaceutical company will earn $5.85 per share for the year. B. Riley has a “Buy” rating and a $54.00 price objective on the stock.

SUPN has been the subject of a number of other research reports. Piper Jaffray Companies reissued a “hold” rating and set a $41.00 target price on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 26th. Cantor Fitzgerald reissued a “buy” rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. FBR & Co started coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $53.00 target price for the company. Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. Finally, SunTrust Banks reissued a “buy” rating and set a $61.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, November 3rd. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $49.90.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded up $3.35 during trading hours on Monday, hitting $46.90. 1,233,700 shares of the stock were exchanged, compared to its average volume of 747,031. The firm has a market capitalization of $2,390.00, a price-to-earnings ratio of 42.64 and a beta of 1.17. Supernus Pharmaceuticals has a 52 week low of $23.10 and a 52 week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. The company had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business’s revenue for the quarter was up 41.5% on a year-over-year basis.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Victor Vaughn sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $42.04, for a total transaction of $630,600.00. Following the completion of the sale, the vice president now directly owns 24,344 shares of the company’s stock, valued at $1,023,421.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 145,750 shares of company stock valued at $6,173,173. Insiders own 6.70% of the company’s stock.

Several large investors have recently bought and sold shares of SUPN. Riverhead Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 91.4% during the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 1,462 shares in the last quarter. Advisor Group Inc. increased its position in shares of Supernus Pharmaceuticals by 13.7% during the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after acquiring an additional 410 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Supernus Pharmaceuticals by 17.7% during the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after acquiring an additional 517 shares in the last quarter. Flinton Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 88.9% during the second quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after acquiring an additional 2,240 shares in the last quarter. Finally, Balyasny Asset Management LLC purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $206,000. 98.26% of the stock is owned by institutional investors.

WARNING: “Equities Analysts Issue Forecasts for Supernus Pharmaceuticals Inc’s FY2022 Earnings (SUPN)” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/22/equities-analysts-issue-forecasts-for-supernus-pharmaceuticals-incs-fy2022-earnings-supn.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply